Artículos de revistas sobre el tema "Pharmaceutical fraud"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Pharmaceutical fraud".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Lu, Zhiqiang, Zaina Parvez Qureshi, Brian Chen, Sudha Xirasagar, Paul Ray, Gowtham Rao, Isaac Lopez et al. "Why Is Cancer Care So Expensive: Potential Implications of Fraud and Abuse". Blood 120, n.º 21 (16 de noviembre de 2012): 4275. http://dx.doi.org/10.1182/blood.v120.21.4275.4275.
Texto completoMa, Jianwei, Na Wang y Qiangzu Li. "The Failure of Kangmei, the Lesson of A-Shares". International Business & Economics Studies 4, n.º 2 (20 de mayo de 2022): p88. http://dx.doi.org/10.22158/ibes.v4n2p88.
Texto completoValverde, José Luis. "Corporate responsibility and pharmaceutical fraud". Pharmaceuticals, Policy and Law 14, n.º 2-4 (2012): 129–56. http://dx.doi.org/10.3233/ppl-120350.
Texto completoHoeksema, HL, J. Troost, DE Grobbee, WM Wiersinga, FCB van Wijmen y EC Klasen. "Fraud in a pharmaceutical trial". Lancet 356, n.º 9243 (noviembre de 2000): 1773. http://dx.doi.org/10.1016/s0140-6736(05)71970-x.
Texto completoLiu, Siyang. "The Impact of Chinas Independent Director System on Corporate Financial Fraud: The Case of Kangmei Pharmaceutical Fraud". Advances in Economics, Management and Political Sciences 4, n.º 1 (21 de marzo de 2023): 621–28. http://dx.doi.org/10.54254/2754-1169/4/2022980.
Texto completoCodaste, Harold L., Charlnette Mae T. Lasiste y Alexander Franco A. Delantar. "Preliminary Fraud Risk Assessment of a Pharmaceutical Distributor". International Journal on Graft and Corruption 2, n.º 1 (23 de enero de 2015): 11–23. http://dx.doi.org/10.7719/ijgc.v2i1.299.
Texto completoChen, Yaling, Shan Xiong y Ting Duan. "A Case Study of Fraud in Xinjiang Ready Health Industry Co.,Ltd. Based on Fraud Triangle Theory". Frontiers in Business, Economics and Management 8, n.º 2 (6 de abril de 2023): 134–38. http://dx.doi.org/10.54097/fbem.v8i2.7127.
Texto completoWhite, Jeb. "Masterminds behind pharmaceutical fraud deserve prison time". Nature Medicine 16, n.º 9 (septiembre de 2010): 956. http://dx.doi.org/10.1038/nm0910-956.
Texto completo., Olivia. "PENGARUH PENGENDALIAN.INTERNAL, INDEPENDENSI, WHISTLEBLOWING SYSTEM, ANTI-FRAUD AWARENESS, DAN INTEGRITAS TERHADAP PENCEGAHAN FRAUD". Jurnal Ekonomi Trisakti 2, n.º 2 (10 de agosto de 2022): 261–72. http://dx.doi.org/10.25105/jet.v2i2.14217.
Texto completoDai, Liqin. "Identification of Financial Fraud in Listed Companies and Analysis of Preventive Measures - A Case Study of Kangmei Pharmaceutical". BCP Business & Management 27 (6 de septiembre de 2022): 350–62. http://dx.doi.org/10.54691/bcpbm.v27i.1982.
Texto completoAkomea-Frimpong, Isaac y Charles Andoh. "Understanding and controlling financial fraud in the drug industry". Journal of Financial Crime 27, n.º 2 (31 de enero de 2020): 337–54. http://dx.doi.org/10.1108/jfc-06-2019-0071.
Texto completoSetiyowati, Supami Wahyu, Mochamad Fariz Irianto y Irma Tyasari. "Determinan Pencegahan Kecurangan Pengelolaan Dana Desa Dimoderasi Kompetensi Aparatur". Organum: Jurnal Saintifik Manajemen dan Akuntansi 5, n.º 1 (30 de junio de 2022): 62–72. http://dx.doi.org/10.35138/organum.v5i1.197.
Texto completoKevorkova, Z. A. y I. A. Zhukova. "HIGH RISK AREAS OF FRAUD ON PHARMACEUTICAL MARKET". Современная экономика проблемы и решения, n.º 2 (2023): 81–90. http://dx.doi.org/10.17308/meps/2078-9017/2023/2/81-90.
Texto completoLi, Yanan. "Identification and Audit Response of Financial Fraud in Listed Companies in Pharmaceutical Industry". Frontiers in Business, Economics and Management 7, n.º 2 (5 de febrero de 2023): 15–19. http://dx.doi.org/10.54097/fbem.v7i2.4353.
Texto completoKesselheim, Aaron S., David M. Studdert y Michelle M. Mello. "Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies". New England Journal of Medicine 362, n.º 19 (13 de mayo de 2010): 1832–39. http://dx.doi.org/10.1056/nejmsr0912039.
Texto completoPeltier-Rivest, Dominic y Carl Pacini. "Detecting counterfeit pharmaceutical drugs". Journal of Financial Crime 26, n.º 4 (7 de octubre de 2019): 1027–47. http://dx.doi.org/10.1108/jfc-06-2018-0057.
Texto completoShalaby, Azza Helmy Mahmoud y Ahmad Abdulkareem Mohammad Al-Harkan. "The awareness of judicial accounting techniques towards the expectations of the external auditor in detecting fraud and its impact on the performance". Accounting 8, n.º 3 (2022): 345–54. http://dx.doi.org/10.5267/j.ac.2021.10.003.
Texto completoQureshi, Zaina P. "Pharmaceutical Fraud and Abuse in the United States, 1996-2010". Archives of Internal Medicine 171, n.º 16 (12 de septiembre de 2011): 1503. http://dx.doi.org/10.1001/archinternmed.2011.397.
Texto completoDewi, Nurul Hasanah Uswati, Putri Wulanditya, Dian Oktarina y Herwin Ardianto. "Banking sector lack detection: Expectation gap between auditors and bankers". Accounting 7, n.º 6 (2021): 1353–62. http://dx.doi.org/10.5267/j.ac.2021.4.002.
Texto completoAnas, Dadio Fiasani y Anastasia Filiana Ismawati. "EFFECT FRAUD DIAMOND THEORY DETECTING FINANCIAL STATEMENT FRAUD WITH PANDEMIC AS CONTROL VARIABLE". JOURNAL OF ACCOUNTING, ENTREPRENEURSHIP AND FINANCIAL TECHNOLOGY (JAEF) 4, n.º 1 (28 de octubre de 2022): 15–28. http://dx.doi.org/10.37715/jaef.v4i1.2754.
Texto completoToothman, Myranda, Ken Moore y Doohee Lee. "Unraveling Medicare and Medicaid Prescription Drug Fraud and Abuse". Compensation & Benefits Review 43, n.º 6 (13 de abril de 2011): 339–45. http://dx.doi.org/10.1177/0886368711405018.
Texto completoAriyanto, Dodik, I. Made Gilang Jhuniantara, Ni Made Dwi Ratnadi, I. Gusti Ayu Made Asri Dwija Putri y Ayu Aryista Dewi. "Detecting fraudulent financial statements in pharmaceutical companies: Fraud pentagon theory perspective". Accounting 7, n.º 7 (2021): 1611–20. http://dx.doi.org/10.5267/j.ac.2021.5.009.
Texto completoBurrell, Darrell Norman, Sharon L. Burton, Delores Springs, Jorja B. Wright, Maurice D. Harmon y Eugene J. M. Lewis. "A Qualitative Research Assessment of the MBA for 2020 and Beyond". International Journal of Smart Education and Urban Society 11, n.º 3 (julio de 2020): 23–41. http://dx.doi.org/10.4018/ijseus.2020070103.
Texto completoHayashi, Merrick Max Dillard. "Pharmaceutical Phonies: The Entanglement of Fraud, Third-Party Payors, and Proximate Cause in Civil RICO Cases". Texas A&M Law Review 9, n.º 4 (13 de diciembre de 2021): 1–11. http://dx.doi.org/10.37419/lr.v9.arg.1.
Texto completoBarrientos, Claudio y Silvana Moris. "Teaching organic nomenclature for pharmacy students: Adapting a course to online mode during COVID-19". Pharmacy Education 22, n.º 1 (28 de mayo de 2022): 360–75. http://dx.doi.org/10.46542/pe.2022.221.360375.
Texto completoRosdini, Dini, Aria Farah Mita y Dyah Setyaningrum. "Internal auditor reports a fraud: Courage and pressure". Accounting 7, n.º 7 (2021): 1813–18. http://dx.doi.org/10.5267/j.ac.2021.6.001.
Texto completoRein, Frederick H. y Joseph B. Crystal. "Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al.: Reformulating an old drug is not as obvious as one might think". Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 9, n.º 1 (marzo de 2012): 36–44. http://dx.doi.org/10.1177/1741134311433733.
Texto completoWidiastika, Audri y Junaidi Junaidi. "Fraud Pentagon dalam Mendeteksi Kecurangan Laporan Keuangan". Jurnal Akuntansi, Keuangan, dan Manajemen 3, n.º 1 (25 de diciembre de 2021): 83–98. http://dx.doi.org/10.35912/jakman.v3i1.747.
Texto completoGreenman, Zac y Dr Cindy Greenman, CFE. "Pharmaceutical Fraud: Off-Label Marketing of Drugs in the United States, 2009-2016". Research in Economics and Management 2, n.º 5 (26 de octubre de 2017): 198. http://dx.doi.org/10.22158/rem.v2n5p198.
Texto completoPatria, Harry. "Predicting Fraudulence Transaction under Data Imbalance using Neural Network (Deep Learning)". Data Science: Journal of Computing and Applied Informatics 6, n.º 2 (31 de julio de 2022): 67–80. http://dx.doi.org/10.32734/jocai.v6.i2-8309.
Texto completoNanda, Satria tri, Neneng Salmiah y Dina Mulyana. "FRAUDULENT FINANCIAL REPORTING: A PENTAGON FRAUD ANALYSIS". Jurnal Ilmiah Ekonomi Dan Bisnis 16, n.º 2 (24 de septiembre de 2019): 122–34. http://dx.doi.org/10.31849/jieb.v16i2.2678.
Texto completoHorowitz, Arthur M. "Fraud and Investigator Integrity in Clinical Research". Clinical Research and Regulatory Affairs 12, n.º 2 (enero de 1995): 131–41. http://dx.doi.org/10.3109/10601339509079583.
Texto completoHaddab, Daniella Maya. "Detecting banking frauds with analytics and machine learning". Business & IT XIII, n.º 1 (2023): 90–96. http://dx.doi.org/10.14311/bit.2023.01.11.
Texto completoBudiman, Monika, Choirul Anwar y Sudjono Sudjono. "FACTORS AFFECTING FRAUD PREVENTION AND ITS IMPLICATION TO THE QUALITY OF FINANCIAL STATEMENTS". Journal of Applied Finance & Accounting 8, n.º 1 (30 de marzo de 2022): 1–25. http://dx.doi.org/10.21512/jafa.v8i1.6858.
Texto completoCarder, Elizabeth B. y Joseph W. Metro. "Appendix A. Minefields for the Unwary: Fraud and Abuse Issues Affecting Pharmaceutical Manufacturers". Journal of Pharmaceutical Marketing & Management 12, n.º 2-3 (enero de 1998): 125–44. http://dx.doi.org/10.3109/j058v12n02_13.
Texto completoQureshi, Z., O. Sartor y C. Bennett. "PHP3 FEDERAL ENFORCEMENT ACTIONS AGAINST FRAUD AND ABUSE BY PHARMACEUTICAL MANUFACTURERS: 1996-2010". Value in Health 14, n.º 3 (mayo de 2011): A12. http://dx.doi.org/10.1016/j.jval.2011.02.077.
Texto completoRazali, Nur Amira Hidayah, Wan Rosalili Wan Rosli y Mohd Bahrin Othman. "The Legal Protection of E-Consumers Against E-Commerce Fraud in Malaysia". Malaysian Journal of Social Sciences and Humanities (MJSSH) 7, n.º 9 (30 de septiembre de 2022): e001778. http://dx.doi.org/10.47405/mjssh.v7i9.1778.
Texto completoFaunce, Thomas A., Gregor Urbas y Lesley Skillen. "Implementing US‐style anti‐fraud laws in the Australian pharmaceutical and health care industries". Medical Journal of Australia 194, n.º 9 (mayo de 2011): 474–78. http://dx.doi.org/10.5694/j.1326-5377.2011.tb03066.x.
Texto completoBraillon, Alain. "Implementing US‐style anti‐fraud laws in the Australian pharmaceutical and health care industries". Medical Journal of Australia 195, n.º 10 (noviembre de 2011): 585. http://dx.doi.org/10.5694/mja11.10601.
Texto completoKhuluqi, Khusnul y Napisah. "Pengaruh Fraud Pentagon Terhadap Kecurangan Laporan Keuangan Dengan Ukuran Perusahaan Sebagai Pemoderasi". WACANA EKONOMI (Jurnal Ekonomi, Bisnis dan Akuntansi) 21, n.º 2 (2 de noviembre de 2022): 198–211. http://dx.doi.org/10.22225/we.21.2.2022.198-211.
Texto completoVictory, Chika Odukwu, Eke Promise y Chukwumati N. Mike. "Impact of Cyber-Security on Fraud Prevention in Nigerian Commercial Banks". Jurnal Akuntansi, Keuangan, dan Manajemen 4, n.º 1 (19 de diciembre de 2022): 15–27. http://dx.doi.org/10.35912/jakman.v4i1.1527.
Texto completoCheng, Ching Hung, Zhe Huang, Siqi Lin y Hangyu Wu. "Analysis of Corporation’s Financial Fraud and Independent Directors’ Decision Based on Evolutionary Game Theory". BCP Business & Management 31 (5 de noviembre de 2022): 195–204. http://dx.doi.org/10.54691/bcpbm.v31i.2561.
Texto completoLiu, Mengna y Jinshi Chen. "A Critical Metaphor Analysis of Anti-telefraud Public Legal Education Discourse". International Journal of Linguistics, Literature and Translation 5, n.º 3 (13 de marzo de 2022): 108–13. http://dx.doi.org/10.32996/ijllt.2022.5.3.14.
Texto completoLlarena, Zharama. "Organized Corporate Crimes using UNCITRAL Arbitration Framework Development for EPC Disclosure concerning Epistemic Corruption and Pharmaceutical Fraud of Off-label Medicines as Health Regulation and Policy". International Journal of Communication and Public Relation 8, n.º 1 (27 de febrero de 2023): 40–55. http://dx.doi.org/10.47604/ijcpr.1787.
Texto completoGabriel, Joseph M. y Bennett Holman. "Clinical trials and the origins of pharmaceutical fraud: Parke, Davis & Company, virtue epistemology, and the history of the fundamental antagonism". History of Science 58, n.º 4 (25 de julio de 2020): 533–58. http://dx.doi.org/10.1177/0073275320942435.
Texto completoMironova, O. I., L. A. Ruonala y E. S. Mironov. "Digitalization of Social Contacts – Risks for Women Seeking a Spouse through Dating Sites and Apps". Psychology and Law 11, n.º 4 (2021): 42–63. http://dx.doi.org/10.17759/psylaw.2021110404.
Texto completoSetiyorini, Ika y Desi Susilawati. "Accounting Information System And Prevention Of Fraudulent Drug Supply At The Kardinah Tegal General Hospital". Proceedings University of Muhammadiyah Yogyakarta Undergraduate Conference 2, n.º 1 (30 de junio de 2022): 45–58. http://dx.doi.org/10.18196/umygrace.v2i1.412.
Texto completoFerguson, Brian. "Fraud and misconduct in medical research Summary of the report of the Royal College of Physicians". Psychiatric Bulletin 16, n.º 10 (octubre de 1992): 628–29. http://dx.doi.org/10.1192/pb.16.10.628.
Texto completoBrondz, Ilia. "Analytical Methods in Quality Control of Scientific Publications Part IV: Fraud Ordered by the Pharmaceutical Industry". International Journal of Analytical Mass Spectrometry and Chromatography 02, n.º 04 (2014): 103–12. http://dx.doi.org/10.4236/ijamsc.2014.24009.
Texto completoShah, Udayan K., Douglas R. Johnston, Gina Maisto Smith, Barbara E. Ziv y James S. Reilly. "Article Commentary: Penalties for health care fraud and abuse: January 2007-March 2008". Otolaryngology–Head and Neck Surgery 140, n.º 5 (mayo de 2009): 625–28. http://dx.doi.org/10.1016/j.otohns.2008.12.032.
Texto completo